RxDoctor Payments Data

Gary Myrthil, MD

Nephrology · Warner Robins, GANPI 1073547766

Payments from drug & device makers

$2,414in general payments, 2019–2025

Across 127 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$369
  • Bayer$279
  • Otsuka America Pharmaceutical, Inc.$278
  • Ardelyx, Inc.$260
  • Amgen$181
  • Vifor Pharma, Inc.$168
  • plus $878 from 16 others

What the payments were for

  • Food & beverage$2,14589%
  • Education$26811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,414 in reported general payments places this provider in the 55th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$217,987
Medicare patients
334
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate29$38,997
VelphoroSucroferric Oxyhydroxide18$35,823
LokelmaSodium Zirconium Cyclosilicate27$25,415
Sevelamer Carbonate67$23,919
OzempicSemaglutide13$12,178
FarxigaDapagliflozin Propanediol16$9,476
KerendiaFinerenone14$9,183
EliquisApixaban12$8,588
JanumetSitagliptin Phos/Metformin Hcl11$5,268
Clonidine16$2,990
Calcium Acetate27$1,747
Calcitriol93$1,465
Candesartan Cilexetil32$1,323
Midodrine Hcl27$1,203
Rosuvastatin Calcium52$1,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$58$38,99729 claims
Fresenius USA Marketing, Inc.Velphoro$152$35,82318 claims
AstraZenecaLokelma, Farxiga$369$34,89143 claims
Novo NordiskOzempic$73$12,17813 claims
BayerKerendia$279$9,18314 claims
MerckJanumet$18$5,26811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 388 nephrology providers in Georgia.

Other nephrology in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →